Loading
Total declarations
Companies
▲ Purchases (21 ops.)
▼ Sales (4 ops.)
Latest filing published 13 Mar 2013 for Pacira BioSciences, Inc., €10.7M.
Insider track record
Disclosed buys
21
Disclosed sells
4
Signal history
No signal scores available.
Closed purchases
Market purchases
21
Positive at T+90
100%
Median T+90
+46.6%
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +50.3%Entry US$7.00 · Close at T+365 US$10.52
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Vaughn M. Kailian: trading record in brief
This profile gathers the share dealings of Vaughn M. Kailian across 3 companies, led by Peplin Inc, Pacira BioSciences, Inc. and Memory Pharmaceuticals Corp. Between 18 December 2006 and 11 March 2013, the trades on record add up to 34 filings.
On the open market, the record shows 21 purchases worth €9.9M and 4 sales worth €10.9M. Netting one side against the other leaves €1.0M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 1 share grant. So far in 2013, the count stands at no purchases and 1 sale.
Half of the purchases are above €9,473 and half below.
The record was last updated on 13 March 2013 with an open-market sale (€10.7M) in Pacira BioSciences, Inc. The last purchase on record was published on 22 November 2011, which is 5,450 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Vaughn M. Kailian
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations18 total
500,000 shares@ US$27.86Common StockSEC:0001209191-13-016172:0
712,567 sharesCommon StockSEC:0001209191-11-010535:1
1,487,680 sharesCommon StockSEC:0001209191-11-010535:0
1,487,680 sharesCommon StockSEC:0001209191-11-008428:0
712,567 sharesCommon StockSEC:0001209191-11-008428:1
267,857 shares@ US$7.00Common StockSEC:0001209191-11-008428:2
Canonical exit: 11 May 2011 (T+90)
267,857 shares@ US$7.00Common StockSEC:0001209191-11-008428:3
Canonical exit: 11 May 2011 (T+90)
3,419,056 sharesCommon StockSEC:0001209191-09-052749:0
999 shares@ US$8.00Common StockSEC:0001209191-09-007923:0
Canonical exit: 10 May 2009 (T+90)
1,598 shares@ US$7.80Common StockSEC:0001209191-09-003975:0
Canonical exit: 15 Apr 2009 (T+90)
7,340 shares@ US$8.20Common StockSEC:0001209191-09-003975:1
Canonical exit: 16 Apr 2009 (T+90)
899 shares@ US$8.20Common StockSEC:0001209191-09-003975:2
Canonical exit: 19 Apr 2009 (T+90)
45 shares@ US$8.40Common StockSEC:0001209191-09-003975:3
Canonical exit: 20 Apr 2009 (T+90)
6,911 shares@ US$7.03Common StockSEC:0001209191-09-003416:0
Canonical exit: 13 Apr 2009 (T+90)
14,138,993 shares@ US$0.61Common StockSEC:0001209191-09-001356:0
00Common StockSEC:0001209191-07-056281:0
00Common StockSEC:0001209191-07-056277:0
2,315,151 shares@ US$1.11Common StockSEC:0001181431-07-002395:0
Canonical exit: 18 Mar 2007 (T+90)
18 of 18 declarations
